Rockwell Medical: Difference between revisions
mNo edit summary |
No edit summary |
||
| Line 22: | Line 22: | ||
| footnotes = <ref name=10K>{{cite web | url=https://www.sec.gov/Archives/edgar/data/1041024/000155837019002200/rmti-20181231x10k.htm | title=Rockwell Medical Inc. 2018 Form 10-K Annual Report | publisher=[[U.S. Securities and Exchange Commission]]}}</ref> |
| footnotes = <ref name=10K>{{cite web | url=https://www.sec.gov/Archives/edgar/data/1041024/000155837019002200/rmti-20181231x10k.htm | title=Rockwell Medical Inc. 2018 Form 10-K Annual Report | publisher=[[U.S. Securities and Exchange Commission]]}}</ref> |
||
}} |
}} |
||
'''Rockwell Medical Inc.''' |
'''Rockwell Medical Inc. is a company''' based in [[Wixom, Michigan]] and founded in 1996 that focuses on development and commercialization of treatments against diseases such as [[end-stage renal disease]] (ESRD) and [[chronic kidney disease]] (CKD). |
||
The company's primary customers are [[Kidney dialysis|dialysis]] providers such as [[DaVita Inc.]] (46% of 2018 revenues).<ref name=10K/> |
The company's primary customers are [[Kidney dialysis|dialysis]] providers such as [[DaVita Inc.]] (46% of 2018 revenues).<ref name=10K/> |
||
The company was founded in 1996.<ref name=10K/> |
|||
==Products== |
==Products== |
||
Revision as of 09:58, 16 June 2023
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Company type | Public company |
|---|---|
| Nasdaq: RMTI Russell 2000 Index component | |
| Industrie | Pharmaceutical industry |
| Gegründet | 1996 |
| Hauptsitz | Wixom, Michigan |
Key people | Stuart Paul, President and CEO Ajay Gupta, Chief Scientific Officer Raymond D. Pratt, Chief Medical Officer |
| Revenue |  $63 million (2018) |
 -$32 million (2018) | |
| Total assets | $52 million (2018) |
| Total equity | $27 million (2018) |
Number of employees | 269 (2018) |
| Website | www |
| Footnotes / references [1] | |
Rockwell Medical Inc. is a company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers such as DaVita Inc. (46% of 2018 revenues).[1]
Produkte
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transported it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market.[2][3][4] In February 2014, the Company completed its long-term safety study for Triferic.[5]
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.[6]
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient’s bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.[6]
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
References
- ^ a b "Rockwell Medical Inc. 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- ^ "Triferic Pharmacokinetics Characterized". Renal and Urology News. 2017-04-20.
- ^ "FDA Drug information" (PDF). FDA.
- ^ "NASDAQ SEC Filing". SEC.
- ^ "Rockwell Medical Completes Long-Term Safety Study for Triferic(TM)".
- ^ a b "NASDAQ | SEC Filing". secfilings.nasdaq.com.